The study team will meet weekly to discuss the trial and evaluate adverse events and unanticipated events. All events will be monitored very closely. The study team will follow injection site reaction, development of Herpes Zoster, hepatic decompensation and any hospitalizations. A thorough history and physical will be done at screening and as needed to reduce the chance of adverse events.